Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease
RationalCastleman disease is a rare lymphoproliferative disorder that can be subdivided into unicentric and multicentric forms, the latter of which causes a spectrum of serious medical conditions. Here, we present a case of idiopathic multicentric Castleman disease in the eighth decade of life. Pati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-01-01
|
| Series: | Case Reports in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2022/1840589 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832562212494901248 |
|---|---|
| author | Stamatios Chrysochoou Andreas Kreft Eberhard Schneider |
| author_facet | Stamatios Chrysochoou Andreas Kreft Eberhard Schneider |
| author_sort | Stamatios Chrysochoou |
| collection | DOAJ |
| description | RationalCastleman disease is a rare lymphoproliferative disorder that can be subdivided into unicentric and multicentric forms, the latter of which causes a spectrum of serious medical conditions. Here, we present a case of idiopathic multicentric Castleman disease in the eighth decade of life. Patient Concerns. First hospitalized due to unexplained progressive anemia, the patient was readmitted to the hospital 18 months later with suspected lymphoma. Clinical examination revealed a progressive lymphadenopathy. Diagnoses. Histopathologic lymph node features, anemia, elevated CRP and IL6 levels, splenomegaly, and hypoalbuminemia indicated multicentric Castleman (MCD) disease. Interventions. The patient was treated intravenously with a dose of 11 mg/kg siltuximab every 3 weeks. Outcomes. Timely correct diagnosis through the stringent use of consensus diagnostic criteria and sufficient siltuximab therapy has considerably promoted favorable clinical outcomes in a patient suffering from MCD. |
| format | Article |
| id | doaj-art-b9908a1ca937405db9af1c4eaa7be376 |
| institution | Kabale University |
| issn | 2090-6579 |
| language | English |
| publishDate | 2022-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Case Reports in Hematology |
| spelling | doaj-art-b9908a1ca937405db9af1c4eaa7be3762025-02-03T01:23:13ZengWileyCase Reports in Hematology2090-65792022-01-01202210.1155/2022/1840589Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman DiseaseStamatios Chrysochoou0Andreas Kreft1Eberhard Schneider2GPR Gesundheits- und Pflegezentrum Rüsselsheim Gemeinnützige GmbHInstitute of PathologyGPR Gesundheits- und Pflegezentrum Rüsselsheim Gemeinnützige GmbHRationalCastleman disease is a rare lymphoproliferative disorder that can be subdivided into unicentric and multicentric forms, the latter of which causes a spectrum of serious medical conditions. Here, we present a case of idiopathic multicentric Castleman disease in the eighth decade of life. Patient Concerns. First hospitalized due to unexplained progressive anemia, the patient was readmitted to the hospital 18 months later with suspected lymphoma. Clinical examination revealed a progressive lymphadenopathy. Diagnoses. Histopathologic lymph node features, anemia, elevated CRP and IL6 levels, splenomegaly, and hypoalbuminemia indicated multicentric Castleman (MCD) disease. Interventions. The patient was treated intravenously with a dose of 11 mg/kg siltuximab every 3 weeks. Outcomes. Timely correct diagnosis through the stringent use of consensus diagnostic criteria and sufficient siltuximab therapy has considerably promoted favorable clinical outcomes in a patient suffering from MCD.http://dx.doi.org/10.1155/2022/1840589 |
| spellingShingle | Stamatios Chrysochoou Andreas Kreft Eberhard Schneider Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease Case Reports in Hematology |
| title | Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease |
| title_full | Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease |
| title_fullStr | Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease |
| title_full_unstemmed | Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease |
| title_short | Siltuximab-Related Favorable Clinical Outcome for a Patient Suffering from Idiopathic Multicentric Castleman Disease |
| title_sort | siltuximab related favorable clinical outcome for a patient suffering from idiopathic multicentric castleman disease |
| url | http://dx.doi.org/10.1155/2022/1840589 |
| work_keys_str_mv | AT stamatioschrysochoou siltuximabrelatedfavorableclinicaloutcomeforapatientsufferingfromidiopathicmulticentriccastlemandisease AT andreaskreft siltuximabrelatedfavorableclinicaloutcomeforapatientsufferingfromidiopathicmulticentriccastlemandisease AT eberhardschneider siltuximabrelatedfavorableclinicaloutcomeforapatientsufferingfromidiopathicmulticentriccastlemandisease |